Clinical trial · Interventional
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Researchers also want to understand how different genetic changes in follicular lymphoma relate to a person's response to the usual first-line treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cfDNA testing | Diagnostic Test | — | UNRESOLVED |
| PET/CT, CT, or MRI testing | Diagnostic Test | — | UNRESOLVED |
| pre-treatment test specimen | Diagnostic Test | — | UNRESOLVED |
| sample of saliva or fingernail clipping | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Prospective Group
- description
- Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
- interventionNames
- Diagnostic Test: cfDNA testing
- Other: sample of saliva or fingernail clipping
- Diagnostic Test: pre-treatment test specimen
- Diagnostic Test: PET/CT, CT, or MRI testing
- type
- EXPERIMENTAL
- label
- Retrospective Group
- description
- Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of s cfDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18 years of age at time of signing informed consent. Consent is permitted from either the participant or from a Legally Authorized Representative (LAR) on their behalf. * Histology-confirmed follicular lymphoma grade 1-3a, verified by the enrolling institution * Ability to adhere to the study visit schedule and all the protocol requirements * Measurable FDG-avid disease * Not applicable for retrospective patients in CR Exclusion Criteria: * Patients receiving second or greater line of therapy (except in retrospective cohort of long-term survivors of FL \[i.e. \>10 years out from frontline treatment\])
References
Publications (0)
Data not yet available